Skip to main content
Erschienen in: Tumor Biology 8/2016

29.01.2016 | Original Article

ΔNp63 regulates cell proliferation, differentiation, adhesion, and migration in the BL2 subtype of basal-like breast cancer

verfasst von: Paulina Orzol, Marta Nekulova, Jitka Holcakova, Petr Muller, Borivoj Votesek, Philip J. Coates

Erschienen in: Tumor Biology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Triple-negative breast cancers (TNBC) comprise a heterogeneous subgroup of tumors with a generally poor prognosis. Subclassification of TNBC based on genomic analyses shows that basal-like TNBCs, specifically the basal A or BL2 subtype, are characterized by the expression of ΔNp63, a transcription factor that has been attributed a variety of roles in the regulation of proliferation, differentiation, and cell survival. To investigate the role(s) of p63 in basal-like breast cancers, we used HCC1806 cells that are classified as basal A/BL2. We show that these cells endogenously express p63, mainly as the ΔNp63α isoform. TP63 gene knockout by CRISPR resulted in viable cells that proliferate more slowly and adhere less tightly, with an increased rate of migration. Analysis of adhesion-related gene expression revealed a complex set of alterations in p63-depleted cells, with both increased and decreased adhesion molecules and adhesion substrates compared to parental cells expressing p63. Examination of the phenotype of these cells indicated that endogenous p63 is required to suppress the expression of luminal markers and maintain the basal epithelial phenotype, with increased levels of both CK8 and CK18 and a reduction in N-cadherin levels in cells lacking p63. On the other hand, the level of CK5 was not decreased and ER was not increased, indicating that p63 loss is insufficient to induce full luminal-type differentiation. Taken together, these data demonstrate that p63 exerts multiple pro-oncogenic effects on cell differentiation, proliferation and adhesion in basal-like breast cancers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157–67.CrossRefPubMed Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157–67.CrossRefPubMed
2.
Zurück zum Zitat Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142–50.CrossRefPubMedPubMedCentral Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142–50.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.CrossRefPubMedPubMedCentral Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–27.CrossRefPubMedPubMedCentral Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–27.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380–8.CrossRefPubMed Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380–8.CrossRefPubMed
6.
Zurück zum Zitat Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001;25:1054–60.CrossRefPubMed Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001;25:1054–60.CrossRefPubMed
7.
Zurück zum Zitat Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688–94.CrossRefPubMed Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688–94.CrossRefPubMed
8.
Zurück zum Zitat Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002;198:417–27.CrossRefPubMed Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002;198:417–27.CrossRefPubMed
9.
Zurück zum Zitat Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol. 2010;5:349–71.CrossRefPubMed Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol. 2010;5:349–71.CrossRefPubMed
10.
Zurück zum Zitat Nekulova M, Holcakova J, Coates P, et al. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011;16:296–327.CrossRefPubMed Nekulova M, Holcakova J, Coates P, et al. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011;16:296–327.CrossRefPubMed
11.
Zurück zum Zitat Orzol P, Holcakova J, Nekulova M, et al. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histol Histopathol. 2015;30:503–21.PubMed Orzol P, Holcakova J, Nekulova M, et al. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histol Histopathol. 2015;30:503–21.PubMed
12.
Zurück zum Zitat Chakrabarti R, Wei Y, Hwang J, et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014;16:1004–15. 1001–1013.CrossRefPubMedPubMedCentral Chakrabarti R, Wei Y, Hwang J, et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014;16:1004–15. 1001–1013.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Memmi EM, Sanarico AG, Giacobbe A, et al. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc Natl Acad Sci U S A. 2015;112:3499–504.CrossRefPubMedPubMedCentral Memmi EM, Sanarico AG, Giacobbe A, et al. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc Natl Acad Sci U S A. 2015;112:3499–504.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Buckley NE, Conlon SJ, Jirstrom K, et al. The {Delta}Np63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Res. 2011;71:1933–44.CrossRefPubMed Buckley NE, Conlon SJ, Jirstrom K, et al. The {Delta}Np63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Res. 2011;71:1933–44.CrossRefPubMed
15.
Zurück zum Zitat Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7:363–73.CrossRefPubMed Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7:363–73.CrossRefPubMed
17.
Zurück zum Zitat Nekulova M, Holcakova J, Nenutil R, et al. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Arch. 2013;463:415–25.CrossRefPubMed Nekulova M, Holcakova J, Nenutil R, et al. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Arch. 2013;463:415–25.CrossRefPubMed
18.
Zurück zum Zitat Senoo M, Pinto F, Crum CP, et al. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 2007;129:523–36.CrossRefPubMed Senoo M, Pinto F, Crum CP, et al. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 2007;129:523–36.CrossRefPubMed
19.
Zurück zum Zitat Boldrup L, Coates PJ, Gu X, et al. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol. 2007;213:384–91.CrossRefPubMed Boldrup L, Coates PJ, Gu X, et al. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol. 2007;213:384–91.CrossRefPubMed
20.
Zurück zum Zitat Romano RA, Ortt K, Birkaya B, et al. An active role of the delta N isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One. 2009;4:e5623.CrossRefPubMedPubMedCentral Romano RA, Ortt K, Birkaya B, et al. An active role of the delta N isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One. 2009;4:e5623.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Aleskandarany MA, Negm OH, Green AR, et al. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Res Treat. 2014;145:339–48.CrossRefPubMed Aleskandarany MA, Negm OH, Green AR, et al. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Res Treat. 2014;145:339–48.CrossRefPubMed
22.
Zurück zum Zitat Carroll DK, Carroll JS, Leong CO, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 2006;8:551–61.CrossRefPubMed Carroll DK, Carroll JS, Leong CO, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 2006;8:551–61.CrossRefPubMed
23.
Zurück zum Zitat Gu X, Coates PJ, Boldrup L, et al. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett. 2008;263:26–34.CrossRefPubMed Gu X, Coates PJ, Boldrup L, et al. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett. 2008;263:26–34.CrossRefPubMed
24.
Zurück zum Zitat Barbieri CE, Tang LJ, Brown KA, et al. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 2006;66:7589–97.CrossRefPubMed Barbieri CE, Tang LJ, Brown KA, et al. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res. 2006;66:7589–97.CrossRefPubMed
25.
Zurück zum Zitat Boldrup L, Coates PJ, Gu X, et al. DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J Pathol. 2009;218:428–36.CrossRefPubMed Boldrup L, Coates PJ, Gu X, et al. DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J Pathol. 2009;218:428–36.CrossRefPubMed
26.
Zurück zum Zitat Carroll DK, Brugge JS, Attardi LD. p63, cell adhesion and survival. Cell Cycle. 2007;6:255–61.CrossRefPubMed Carroll DK, Brugge JS, Attardi LD. p63, cell adhesion and survival. Cell Cycle. 2007;6:255–61.CrossRefPubMed
27.
Zurück zum Zitat Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305–16.CrossRefPubMed Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305–16.CrossRefPubMed
28.
Zurück zum Zitat Yang A, Zhu Z, Kapranov P, et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell. 2006;24:593–602.CrossRefPubMed Yang A, Zhu Z, Kapranov P, et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell. 2006;24:593–602.CrossRefPubMed
29.
Zurück zum Zitat Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708–13.CrossRefPubMed Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708–13.CrossRefPubMed
30.
Zurück zum Zitat Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714–8.CrossRefPubMed Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714–8.CrossRefPubMed
31.
Zurück zum Zitat Li N, Singh S, Cherukuri P, et al. Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. Stem Cells. 2008;26:1253–64.CrossRefPubMedPubMedCentral Li N, Singh S, Cherukuri P, et al. Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. Stem Cells. 2008;26:1253–64.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Yalcin-Ozuysal O, Fiche M, Guitierrez M, et al. Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. Cell Death Differ. 2010;17:1600–12.CrossRefPubMed Yalcin-Ozuysal O, Fiche M, Guitierrez M, et al. Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. Cell Death Differ. 2010;17:1600–12.CrossRefPubMed
33.
34.
Zurück zum Zitat Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell. 2002;2:607–16.CrossRefPubMed Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell. 2002;2:607–16.CrossRefPubMed
35.
Zurück zum Zitat Wu G, Nomoto S, Hoque MO, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003;63:2351–7.PubMed Wu G, Nomoto S, Hoque MO, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003;63:2351–7.PubMed
36.
Zurück zum Zitat Mehta R, Jain RK, Sneige N, et al. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol. 2010;63:744–7.CrossRefPubMed Mehta R, Jain RK, Sneige N, et al. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol. 2010;63:744–7.CrossRefPubMed
37.
Zurück zum Zitat Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007;50:434–8.CrossRefPubMed Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007;50:434–8.CrossRefPubMed
38.
Zurück zum Zitat Balboni AL, Hutchinson JA, DeCastro AJ, et al. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res. 2013;73:1020–30.CrossRefPubMed Balboni AL, Hutchinson JA, DeCastro AJ, et al. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res. 2013;73:1020–30.CrossRefPubMed
39.
Zurück zum Zitat Dang TT, Esparza MA, Maine EA, et al. DeltaNp63alpha promotes breast cancer cell motility through the selective activation of components of the epithelial-to-mesenchymal transition program. Cancer Res. 2015;75:3925–35.CrossRefPubMedPubMedCentral Dang TT, Esparza MA, Maine EA, et al. DeltaNp63alpha promotes breast cancer cell motility through the selective activation of components of the epithelial-to-mesenchymal transition program. Cancer Res. 2015;75:3925–35.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Tran MN, Choi W, Wszolek MF, et al. The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013;288:3275–88.CrossRefPubMed Tran MN, Choi W, Wszolek MF, et al. The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013;288:3275–88.CrossRefPubMed
41.
Zurück zum Zitat Alexandrova EM, Petrenko O, Nemajerova A, et al. DeltaNp63 regulates select routes of reprogramming via multiple mechanisms. Cell Death Differ. 2013;20:1698–708.CrossRefPubMedPubMedCentral Alexandrova EM, Petrenko O, Nemajerova A, et al. DeltaNp63 regulates select routes of reprogramming via multiple mechanisms. Cell Death Differ. 2013;20:1698–708.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat McDonald OG, Wu H, Timp W, et al. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol. 2011;18:867–74.CrossRefPubMedPubMedCentral McDonald OG, Wu H, Timp W, et al. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol. 2011;18:867–74.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339:1567–70.CrossRefPubMed Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339:1567–70.CrossRefPubMed
Metadaten
Titel
ΔNp63 regulates cell proliferation, differentiation, adhesion, and migration in the BL2 subtype of basal-like breast cancer
verfasst von
Paulina Orzol
Marta Nekulova
Jitka Holcakova
Petr Muller
Borivoj Votesek
Philip J. Coates
Publikationsdatum
29.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4880-x

Weitere Artikel der Ausgabe 8/2016

Tumor Biology 8/2016 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.